•Using routine blood tests to predict severe immune-related adverse events during immune checkpoint inhibitor treatment
•Integrative multi-omics analysis identifies genetically supported druggable targets for inflammatory bowel disease
•Design and biological evaluation of mesalamine-NSAID hybrids targeting the NLRP3 inflammasome: a multi-target strategy for ulcerative colitis therapy
•Network pharmacology and molecular dynamics simulation elucidate the potential mechanism of Batatasin-III in Bletilla striata against ulcerative colitis
•Exploring nurse-patient mutuality in inflammatory bowel disease: a multicenter cross-sectional study